Stryker Corp. Hits New 52-Week Low at USD 281.04

Stryker Corp., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 281.04 on May 11, 2026. This significant decline marks a notable downturn for the stock, which has experienced a one-year performance drop of 18.84%, contrasting sharply with the S&P 500's impressive gain of 30.97% during the same period. With a market capitalization of USD 133,773 million, Stryker Corp. is classified as a large-cap company. The stock currently has a price-to-earnings (P/E) ratio of 33.00, indicating a premium valuation relative to its earnings. The company maintains a dividend yield of 0.97% and a debt-to-equity ratio of 0.53, reflecting a solid financial position with manageable debt levels. Despite the recent price decline, Stryker Corp. has shown resilience in its profitability, with a return on equity of 17.83% and a profit increase of 18.8% over the past year. However, the stock's performance has been below par in both the long and near term, raising questions about its market position moving forward.